Notable Analyst Rating Changes 2/17: (SRPT) (MU) (CCG) Upgraded; (IMAX) (CVC) (JWN) Downgraded
Tweet Send to a Friend
UPGRADES
BofA/Merrill Lynch boosts Sarepta Therapeutic (Nasdaq: SRPT) from Neutral to Buy and moves its price target from $19 to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BofA/Merrill Lynch boosts Sarepta Therapeutic (Nasdaq: SRPT) from Neutral to Buy and moves its price target from $19 to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
